90K Predicts the Prognosis of Glioma Patients and Enhances Tumor Lysate-pulsed DC Vaccine for Immunotherapy of GBM

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Mar 9

PMID 33686953

Citations 2

Authors

Yu Zeng

Xin Chen

Affiliations

Soon will be listed here.

Abstract

Objectives: This study aimed to investigate the relationship between 90K expression with glioma malignancy and prognosis. Additionally, the enhancement effect of 90K in the Dendritic cell (DC) vaccine for Immunotherapy of glioblastoma (GBM) was evaluated .

Methods: The expression of 90K protein in glioma tissues was detected by western blot. The relationship between the 90K expression and the tumor grade as well as the prognosis of patients was further analyzed by mining TCGA and CGGA database. The concentration of IL-12p70 and IL-10 was detected by ELISA. T lymphocyte proliferation and lethal effect of cytotoxic T cell (CTL) were detected by CCK-8.

Results: The expression of 90K was significantly higher in glioma than normal tissue and increased with tumor grade (P< 0.05). Higher 90K expression was observed in IDH wildtype glioma than IDH mutant and predicted worse overall survival for glioma patients. The concentration of IL-12p70 and IFN-γ was the highest in the Apoptosis U251-90K-DC group, in which group the ability to kill U251 cells by CTL was also the strongest.

Conclusion: 90K was a useful biomarker for glioma malignancy and patient prognosis. The appearance of 90K enhanced the effect of Apoptosis U251-DC vaccine for immunotherapy of GBM.

Citing Articles

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).

Yalamarty S, Filipczak N, Li X, Subhan M, Parveen F, Ataide J Cancers (Basel). 2023; 15(7).

PMID: 37046777 PMC: 10093719. DOI: 10.3390/cancers15072116.

Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review.

Esemen Y, Awan M, Parwez R, Baig A, Rahman S, Masala I Int J Mol Sci. 2022; 23(5).

PMID: 35269752 PMC: 8910150. DOI: 10.3390/ijms23052607.

References

Rea A, Palmieri G, Tinari N, Natoli C, Tagliaferri P, Morabito A . 90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. Oncol Rep. 2011; 1(4):723-5. DOI: 10.3892/or.1.4.723. View

Kim J, Kane J, Panek W, Young J, Rashidi A, Yu D . A Dendritic Cell-Targeted Adenoviral Vector Facilitates Adaptive Immune Response Against Human Glioma Antigen (CMV-IE) and Prolongs Survival in a Human Glioma Tumor Model. Neurotherapeutics. 2018; 15(4):1127-1138. PMC: 6277295. DOI: 10.1007/s13311-018-0650-3. View

Lodermeyer V, Ssebyatika G, Passos V, Ponnurangam A, Malassa A, Ewald E . The Antiviral Activity of the Cellular Glycoprotein LGALS3BP/90K Is Species Specific. J Virol. 2018; 92(14). PMC: 6026745. DOI: 10.1128/JVI.00226-18. View

Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N . Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer. 2002; 95(9):1954-62. DOI: 10.1002/cncr.10899. View

Liau L, Prins R, Kiertscher S, Odesa S, Kremen T, Giovannone A . Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005; 11(15):5515-25. DOI: 10.1158/1078-0432.CCR-05-0464. View

Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B . Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. Oncoimmunology. 2017; 6(11):e1356964. PMC: 5674955. DOI: 10.1080/2162402X.2017.1356964. View

Takeda K, Nakayama M, Hayakawa Y, Kojima Y, Ikeda H, Imai N . IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun. 2017; 8:14607. PMC: 5333095. DOI: 10.1038/ncomms14607. View

Kou Y, Koag M, Cheun Y, Shin A, Lee S . Application of hypoiodite-mediated aminyl radical cyclization to synthesis of solasodine acetate. Steroids. 2012; 77(11):1069-74. DOI: 10.1016/j.steroids.2012.05.002. View

Finocchiaro G, Pellegatta S . Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. Cancer Immunol Immunother. 2015; 65(1):101-9. PMC: 11029491. DOI: 10.1007/s00262-015-1754-9. View

10.

Qiao G, Wang X, Zhou L, Zhou X, Song Y, Wang S . Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. Clin Cancer Res. 2018; 25(5):1494-1504. DOI: 10.1158/1078-0432.CCR-18-2360. View

11.

Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn M . Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10):987-96. DOI: 10.1056/NEJMoa043330. View

12.

Reap E, Suryadevara C, Batich K, Sanchez-Perez L, Archer G, Schmittling R . Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. Cancer Res. 2017; 78(1):256-264. PMC: 5754236. DOI: 10.1158/0008-5472.CAN-17-0469. View

13.

Strizzi L, Muraro R, Vianale G, Natoli C, Talone L, Catalano A . Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival. J Pathol. 2002; 197(2):218-23. DOI: 10.1002/path.1125. View

14.

Tanyi J, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R . Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10(436). DOI: 10.1126/scitranslmed.aao5931. View

15.

Lim M, Xia Y, Bettegowda C, Weller M . Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018; 15(7):422-442. DOI: 10.1038/s41571-018-0003-5. View

16.

Natoli C, Iacobelli S, Kohn L . The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun. 1996; 225(2):617-20. DOI: 10.1006/bbrc.1996.1219. View

17.

Kheshtchin N, Arab S, Ajami M, Mirzaei R, Ashourpour M, Mousavi N . Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer. Cancer Immunol Immunother. 2016; 65(10):1159-67. PMC: 11029746. DOI: 10.1007/s00262-016-1879-5. View

18.

Lee J, Lee M, Garon E, Goldman J, Salehi-Rad R, Baratelli F . Phase I Trial of Intratumoral Injection of Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8 T-cell Infiltration. Clin Cancer Res. 2017; 23(16):4556-4568. PMC: 5599263. DOI: 10.1158/1078-0432.CCR-16-2821. View

19.

Iacobelli S, Sismondi P, Giai M, DEgidio M, Tinari N, Amatetti C . Prognostic value of a novel circulating serum 90K antigen in breast cancer. Br J Cancer. 1994; 69(1):172-6. PMC: 1968766. DOI: 10.1038/bjc.1994.29. View

20.

Adhikaree J, Franks H, Televantos C, Vaghela P, Kaur A, Walker D . Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition - implications for the next generation of DC vaccines. Oncoimmunology. 2019; 8(7):1593803. PMC: 6527277. DOI: 10.1080/2162402X.2019.1593803. View